Catastrophic APS in the Context of Other Thrombotic Microangiopathies

Current Rheumatology Reports

Volumn 17, Issue 1, 2015, Pages

  Rodríguez Pintó, Ignasi ^a   Espinosa, Gerard ^a   Cervera, Ricard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Anticardiolipin; Antiphospholipid; APS; CAPS; Catastrophic antiphospholipid syndrome; Lupus anticoagulant; Microangiopathic anemia; Microangiopathic hemolytic anemia; Microangiopathy; Microthrombosis; Syndromes of thrombotic microangiopathy; Thrombotic microangiopathy; TMA

Indexed keywords

PHOSPHOLIPID ANTIBODY; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE MARKER; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG INDUCED DISEASE; ENZYME ACTIVITY; ENZYME ASSAY; HELLP SYNDROME; HEMOLYTIC UREMIC SYNDROME; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MALIGNANT HYPERTENSION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; REVIEW; SEPSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; COMPLICATION; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HYPERTENSION, MALIGNANT; INFECTION; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOTIC MICROANGIOPATHIES;

ANTIPHOSPHOLIPID SYNDROME; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; HYPERTENSION, MALIGNANT; INFECTION; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOTIC MICROANGIOPATHIES;

EID: 84921888665     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-014-0482-z     Document Type: Review

References (101)

1. Symmers WS. Thrombotic microangiopathic haemolytic anaemia (thrombotic microangiopathy). Br Med J. 1952;2:897–903.
2. George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost. 2013;39:153–60. A thorough and important review of microangiopathic hemolytic anemias.
3. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654–66. An important and recent up-to-date review of primary TMA syndromes.
4. Cervera R, Rodríguez-Pintó I, Colafrancesco S, Conti F, Valesini G, Rosário C, et al. 14th International Congress on Antiphospholipid Antibodies Task Force report on catastrophic antiphospholipid syndrome. Autoimmun Rev. 2014;13:699–707. A recent review of the state-of-the-art catastrophic APS and the differential diagnosis entities of this syndrome.
5. Cervera R, Bucciarelli S, Plasín MA, Gómez-Puerta JA, Plaza J, Pons-Estel G, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun. 2009;32:240–5.
6. Asherson RA, Cervera R. Microvascular and microangiopathic antiphospholipid-associated syndromes (“MAPS”): semantic or antisemantic? Autoimmun Rev. 2008;7:164–7.
7. Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2014;1–8.
8. Espinosa G, Bucciarelli S, Asherson RA, Cervera R. Morbidity and mortality in the catastrophic antiphospholipid syndrome: pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost. 2008;34:290–4.
9. Asherson RA. The catastrophic antiphospholipid syndrome. J Rheumatol. 1992;19:508–12.
10. Cervera R. CAPS Registry. Lupus. 2012;21:755–7.
11. Asherson RA, Espinosa G, Cervera R, Font J, Reverter JC. Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. J Clin Rheumatol. 2002;8:157–65.
12. Asherson R, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530–4.
13. Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000;15:145–51.
14. Agostinis C, Biffi S, Garrovo C, Durigutto P, Lorenzon A, Bek A, et al. In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions. Blood. 2011;118:4231–8.
15. Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries; an undescribed disease. Am J Med. 1952;13:567–9.
16. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr. 1955;85:905–9.
17. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600.
18. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223–34.
19. Arbus GS. Association of verotoxin-producing E. coli and verotoxin with hemolytic uremic syndrome. Kidney Int Suppl. 1997;58:S91–6.
20. Bhimma R, Rollins NC, Coovadia HM, Adhikari M. Post-dysenteric hemolytic uremic syndrome in children during an epidemic of Shigella dysentery in Kwazulu/Natal. Pediatr Nephrol. 1997;11:560–4.
21. Milford DV, Taylor CM, Guttridge B, Hall SM, Rowe B, Kleanthous H. Haemolytic uraemic syndromes in the British Isles 1985–8: association with verocytotoxin producing Escherichia coli. Part 1: clinical and epidemiological aspects. Arch Dis Child. 1990;65:716–21.
22. Moake JL. Haemolytic-uraemic syndrome: basic science. Lancet. 1994;343:393–7.
23. Morigi M, Galbusera M, Binda E, Imberti B, Gastoldi S, Remuzzi A, et al. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood. 2001;98:1828–35.
24. Rodríguez de Córdoba S, Hidalgo MS, Pinto S, Tortajada A. Genetics of atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost. 2014;40:422–30.
25. Espinosa G, Bucciarelli S, Cervera R, Lozano M, Reverter J-C, de la Red G, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730–6.
26. Amoura Z, Costedoat-Chalumeau N, Veyradier A, Wolf M, Ghillani-Dalbin P, Cacoub P, et al. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthritis Rheum. 2004;50:3260–4.
27. Matsuda J, Sanaka T, Gohchi K, Matsui K, Uchida S, Matsumoto M, et al. Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus erythematosus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand factor-cleaving protease. Lupus. 2002;11:463–4.
28. Montecucco C, Di Lauro M, Bobbio-Pallavicini E, Longhi M, Caporali R, De Gennaro F, et al. Anti-phospholipid antibodies and thrombotic thrombocytopenic purpura. Clin Exp Rheumatol. 1987;5:355–8.
29. Ardiles LG, Olavarría F, Elgueta M, Moya P, Mezzano S. Anticardiolipin antibodies in classic pediatric hemolytic-uremic syndrome: a possible pathogenic role. Nephron. 1998;78:278–83.
30. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.
31. Bianchi V, Robles R, Alberio L, Furlan M, La B. Brief report: Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. 2002;100:710–3.
32. Kobayashi T, Wada H, Kamikura Y, Matsumoto T, Mori Y, Kaneko T, et al. Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura. Thromb Res. 2007;119:447–52.
33. Austin SK, Starke RD, Lawrie AS, Cohen H, Machin SJ, Mackie IJ. The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction. Br J Haematol. 2008;141:536–44.
34. Klonizakis P, Tselios K, Sarantopoulos A, Gougourellas I, Rouka E, Onufriadou Z, et al. ADAMTS-13 metalloprotease abnormalities in systemic lupus erythematosus: is there a correlation with disease status? Lupus. 2013;22:443–52.
35. Rieger M, Mannucci PM, Hovinga JAK, Herzog A, Gerstenbauer G, Konetschny C, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. 2005;106:1262–7.
36. Eikelboom JW, Weitz JI. The mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014;371:369–71. A recent publication pointing to a new intracellular pathway that may be important in APS and, interestingly, in CAPS.
37. Nochy D, Daugas E, Droz D, Beaufils H, Grünfeld JP, Piette JC, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol. 1999;10:507–18.
38. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost. 2013;39:559–66.
39. Levi M. The coagulant response in sepsis. Clin. Chest Med. Elsevier Ltd; 2008;29:627–42, viii.
40. Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res. 2003;60:26–39.
41. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006;367:1075–9.
42. Smeeth L, Ph D, Thomas SL, Hall AJ, Hubbard R, Farrington P, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611–8.
43. Brandt J, Wong C, Mihm S, Roberts J, Smith J, Brewer E, et al. Invasive pneumococcal disease and hemolytic uremic syndrome. Pediatrics. 2002;110:371–6.
44. Cervera R, Asherson RA, Acevedo ML, Gómez-Puerta JA, Espinosa G, De La Red G, et al. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis. 2004;63:1312–7.
45. Shoenfeld Y, Blank M, Cervera R, Font J, Raschi E, Meroni P-L. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis. 2006;65:2–6.
46. Asano Y, Sarukawa M, Idezuki T, Harada S, Kaji K, Nakasu I, et al. Multiple small pulmonary emboli associated with transient antiphospholipid syndrome in human Parvovirus B19 infection. Clin Rheumatol. 2006;25:585–7.
47. Uthman I, Tabbarah Z, Gharavi AE. Hughes syndrome associated with cytomegalovirus infection. Lupus. 1999;8:775–7.
48. Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 2012;91:195–205.
49. George JN. Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia. Oncology (Williston Park). 2011;25:908–14.
50. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107:I9–16.
51. Goldberg RJ, Nakagawa T, Johnson RJ, Thurman JM. The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis. 2010;56:1168–74.
52. Miesbach W, Scharrer I, Asherson R. Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies. Clin Rheumatol. 2006;25:840–4.
53. Bazzan M, Montaruli B, Vaccarino A, Fornari G, Saitta M, Prandoni P. Presence of low titre of antiphospholipid antibodies in cancer patients: a prospective study. Intern Emerg Med. 2009;4:491–5.
54. Font C, Vidal L, Espinosa G, Tàssies D, Monteagudo J, Farrús B, et al. Solid cancer, antiphospholipid antibodies, and venous thromboembolism. Autoimmun Rev Elsevier BV. 2011;10:222–7.
55. Vassalo J, Spector N, de Meis E, Rabello LSCF, Rosolem MM, do Brasil PE, et al. Antiphospholipid antibodies in critically ill patients with cancer: a prospective cohort study. J Crit Care. 2014;29:533–8.
56. Pusterla S, Previtali S, Marziali S, Cortelazzo S, Rossi A, Barbui T, et al. Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J. 2004;5:341–6.
57. Miesbach W, Asherson RA, Cervera R, Shoenfeld Y, Gomez Puerta J, Bucciarelli S, et al. The catastrophic antiphospholipid (Asherson’s) syndrome and malignancies. Autoimmun Rev. 2006;6:94–7.
58. Taylor FB Jr, Toh C, Hoots WK, Wada H, Levi M. Scientific and Standardization Committee Communications: On Behalf of the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. 2001;1327–30.
59. Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med. 2014;370:847–59.
60. Asherson RA, Espinosa G, Cervera R, Gómez-Puerta JA, Musuruana J, Bucciarelli S, et al. Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Ann Rheum Dis. 2005;64:943–6.
61. Milne F, Redman C, Walker J, Baker P, Bradley J, Cooper C, et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ. 2005;330:576–80.
62. Martin JN, Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol. 2006;195:914–34.
63. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 2003;102:181–92.
64. Knight M, Nelson-Piercy C, Kurinczuk JJ, Spark P, Brocklehurst P. A prospective national study of acute fatty liver of pregnancy in the UK. Gut. 2008;57:951–6.
65. Vigil-De GP. Acute fatty liver and HELLP syndrome: two distinct pregnancy disorders. Int J Gynaecol Obstet. 2001;73:215–20.
66. Abou-Nassar K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res. 2011;128:77–85.
67. Yamada H, Atsumi T, Kobashi G, Ota C, Kato EH, Tsuruga N, et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol. 2009;79:188–95.
68. Yamada H, Atsumi T, Amengual O, Koike T, Furuta I, Ohta K, et al. Anti-beta2 glycoprotein-I antibody increases the risk of pregnancy-induced hypertension: a case-controlled study. J Reprod Immunol. 2010;84:95–9.
69. Ferrer-Oliveras R, Llurba E, Cabero-Roura L, Alijotas-Reig J. Prevalence and clinical usefulness of antiphospholipid and anticofactor antibodies in different Spanish preeclampsia subsets. Lupus. 2012;21:257–63.
70. Chauleur C, Galanaud J-P, Alonso S, Cochery-Nouvellon E, Balducchi J-P, Marès P, et al. Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodies. J Thromb Haemost. 2010;8:699–706.
71. De Jesus GR, Agmon-Levin N, Andrade CA, Andreoli L, Chighizola CB, Porter TF, et al. 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev. 2014;13:795–813. A recent publication with deep review on obstetric APS and consensus agreement management.
72. Appenzeller S, Souza FHC, Wagner Silva de Souza A, Shoenfeld Y, de Carvalho JF. HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. Semin Arthritis Rheum. 2011;41:517–23.
73. Gómez-Puerta JA, Cervera R, Espinosa G, Asherson RA, García-Carrasco M, da Costa IP, et al. Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis. 2007;66:740–6.
74. Gómez-Puerta JA, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: diagnosis and management in pregnancy. Clin Lab Med. 2013;33:391–400.
75. Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci. 1974;268:336–45.
76. Van den Born B-JH, Koopmans RP, Groeneveld JO, van Montfrans GA. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens. 2006;24:2299–304.
77. Cooling L, Gay S, Silver S. Transfusion medicine illustrated: an imPRESsive mimic. Transfusion. 2010;50:11–2.
78. Sanerkin NG. Vascular lesions of malignant essential hypertension. J Pathol. 1971;103:177–84.
79. Tektonidou MG. Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy. Clin Rev Allergy Immunol. 2009;36:131–40.
80. Ribera L, Vallvé M, Almirall J. Primary antiphospholipid syndrome associated with malignant hypertension. Nefrologia. 2004;3(24 Suppl):93–6.
81. Starakis I, Mazokopakis E, Siagris D, Liossis S, Karatza C, Antonopoulos A. Catastrophic antiphospholipid syndrome presented with severe hypertension, adult respiratory distress syndrome and unilateral adrenal haemorrhagic infarction. Rheumatol Int. 2007;27:781–3.
82. Pons-Estel GJ, Cervera R. Renal involvement in antiphospholipid syndrome. Curr Rheumatol Rep. 2014;16:397. A recent review of renal manifestations in APS.
83. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006;355:809–17.
84. Gruel Y. Antiphospholipid syndrome and heparin-induced thrombocytopenia: update on similarities and differences. J Autoimmun. 2000;15:265–8.
85. Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158:323–35. A thorough discussion of the current management of TTP and other TMHA.
86. McKenzie SE, Sachais BS. Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia. Curr Opin Hematol. 2014;21:380–7.
87. Bourhim M, Darnige L, Legallais C, Arvieux J, Cevallos R, Pouplard C, et al. Anti-beta2-glycoprotein I antibodies recognizing platelet factor 4-heparin complex in antiphospholipid syndrome in patient substantiated with mouse model. J Mol Recognit. 2003;16:125–30.
88. De Larrañaga G, Martinuzzo M, Bocassi A, Fressart MM, Forastiero R. Heparin-platelet factor 4 induced antibodies in patients with either autoimmune or alloimmune antiphospholipid antibodies. Thromb Haemost. 2002;88:371–3.
89. Alpert D, Mandl LA, Erkan D, Yin W, Peerschke EI, Salmon JE. Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome. Ann Rheum Dis. 2008;67:395–401.
90. Martinuzzo ME, Forastiero RR, Adamczuk Y, Pombo G, Carreras LO. Antiplatelet factor 4–heparin antibodies in patients with antiphospholipid antibodies. Thromb Res. 1999;95:271–9.
91. Martin-Toutain I, Piette JC, Diemert MC, Faucher C, Jobic L, Ankri A. High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia. Lupus. 2007;16:79–83.
92. Gelisse E, Gratia E, Just B, Mateu P. Catastrophic antiphospholipid syndrome and heparin-induced thrombocytopenia presenting with adrenal insufficiency caused by bilateral hemorrhagic adrenal infarction during sepsis. Ann Fr Anesth Reanim. 2014;33:e83–4.
93. Podolak B, Blickstein D, Inbal A, Eizner S, Rahamimov R, Yussim A, et al. Renal transplantation in a patient with catastrophic antiphospholipid syndrome and heparin-induced thrombocytopenia. Isr Med Assoc J. 2014;16:61–2.
94. Jacob S, Dunn BL, Qureshi ZP, Bandarenko N, Kwaan HC, Pandey DK, et al. Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012;38:845–53.
95. Zarifian A, Meleg-Smith S, O’Donovan R, Tesi RJ, Batuman V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int. 1999;55:2457–66.
96. Stroncek DF, Vercellotti GM, Hammerschmidt DE, Christie DJ, Shankar RA, Jacob HS. Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis. Blood. 1992;80:241–8.
97. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129–36.
98. Dlott JS, Roubey RAS. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Curr Rheumatol Rep. 2012;14:71–8.
99. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007;86:242–51.
100. Faillace C, de Carvalho JF. Antiphospholipid syndrome development after rituximab treatment. Joint Bone Spine. 2012;79:200–1.
101. Oberic L, Buffet M, Schwarzinger M, Veyradier A, Clabault K, Malot S, et al. Cancer awareness in atypical thrombotic microangiopathies. Oncologist. 2009;14:769–79.